PracticeUpdate: Conference Series - EHA 2018

PracticeUpdate is guided by a world-renowned Editorial and Advisory Board that represents community practitioners and academic specialists with cross-disciplinary expertise. Editor-in-Chief Lee Schwartzberg MD, FACP, Michael Kroll MD Associate Editors Isabel Cunningham MD , Axel Grothey MD Rakhi Naik MD, MHS, Cristhiam Rojas Hernandez MD Advisory Board Benjamin Anderson MD FACS , Roxana Dronca MD , Wilfried Eberhardt MD , Wafiq S. El-Deiry MD PhD FACP , Rafael Fonseca MD , Andre Goy MD, Annette Hasenburg Prof. Dr. med, David Henry MD , Eric Jonasch MD , Jeffrey Kirshner MD FACP , Howard Scher MD , David Straus MD , Roger Stupp MD , Sara M. Tolaney MD MPH Editorial Contributors Neil Majithia MD , Jarushka Naidoo MD , Moshe Ornstein MD , Erin Schenk MD PhD , Basem M. William MD MRCP(UK) , Jeffrey Wiisanen MD, Kelly Casteel MD, Eric Fountain MD, MA PracticeUpdate ® is a registered trademark of Elsevier Inc. 2018 Elsevier Inc. All rights reserved. ABOUT For a complete listing of disclosures for each board member and editorial contributor, please refer to their profile on PracticeUpdate.com PracticeUpdate ’smission is tohelpmedicalprofessionalsnavigate thevast array of available literature and focus on the most critical information for their patients and practice. PracticeUpdate Conference Series is a collection of key research from leading international conferences, reviewed by the PracticeUpdate editorial and advisory board, made available in print format. These news highlights and more are also available online at PracticeUpdate.com PracticeUpdate and the PracticeUpdate Conference Series are commercially supported by advertising, sponsorship, and educational grants. Individual access to PracticeUpdate.com is free. Premium content is available to any user who registers with the site. While PracticeUpdate is a commercially-sponsored product, it maintains the highest level of academic rigour, objectivity, and fair balance associated with all Elsevier products. No editorial content is influenced in any way by commercial sponsors or content contributors. DISCLAIMER The PracticeUpdate Conference Series provides highlights of key international conferences for specialist medical professionals. The ideas and opinions expressed in this publication do not necessarily reflect those of thePublisher.Elsevierwillnotassumeresponsibility fordamages, loss,or claimsofanykindarising fromorrelated to the informationcontained in this publication, including any claims related to the products, drugs, or services mentioned herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Please consult the full current Data Sheet before prescribing any medication mentioned in this publication. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. The production and distribution of this publication is sponsored by Janssen New Zealand. It contains content published in accordance with the editorial policies of Elsevier’s PracticeUpdate.com Content was produced by Elsevier with no involvement by Janssen New Zealand. Allcontentprinted in thispublicationcanbe foundonPracticeUpdate.com SALES Fleur Gill fleur.gill@elsevier.com Linnea Mitchell-Taverner l.mitchell@elsevier.com PRODUCTION Content was originally published on PracticeUpdate.com Production of this issue was executed by: Editorial Manager A nne Neilson anne.neilson@elsevier.com Editorial Project Manager Carolyn Ng Designer Jana Sokolovskaja Cover: illustration of a cancer cell and lymphocytes/istock.com ISSN 2208-150X (Print) • ISSN 2208-1518 (Online)

© EHA 2018

Contents

EHA 2018 • 14–17 June 2018 • Stockholm, Sweden BY THE PRACTICEUPDATE EDITORIAL TEAM

3

13

3 Neither Myeloablative nor Reduced- Intensity Conditioning Impact Overall Survival in T-Cell Lymphoma 4 Tisagenlecleucel Improves Quality of Life for Young Patients with Refractory B-Cell Acute Lymphoblastic Leukemia 4 Consider Obinutuzumab Plus Chlorambucil for First-Line Treatment for CLL 6 Low-Dose Heparin May Be Warranted in Patients Undergoing Lower Limb Surgical Revascularization 7 CLL1-CD33 cCAR T-cell Therapy Promising for AML 8 Erythropoietin Treatment More Effective in Myelofibrosis Patients with Anemia and V617F JAK2 Mutations 9 Nilotinib and Lower-Intensity Chemotherapy Promising Treatment for Ph+ Acute Lymphoblastic Leukemia

10 Consider Interventions to Reduce Weight in Patients With Myeloproliferative Neoplasms 11 EUTOS Long-Term Survival Score Superior for Prognosis of Survival in CML 12 Consider Ibrutinib-Rituximab (IR) as Standard Therapeutic Option for Waldenstrom’s Macroglobulinemia 13 Use of Ruxolitinib–Hydroxyurea Benefits Patients with Myelofibrosis 14 HLH Patients Who Survive First Critical Period May Have Low Relapse Risk 14 Rituximab Yields Durable Response in Adults With Persistent or Chronic Immune Thrombocytopenia

ELSEVIER AUSTRALIA ABN 70 001 002 357 Level 12, Tower 1, 475 Victoria Avenue Chatswood NSW 2067 Australia Printed in Australia. EMCS071801